<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816022</url>
  </required_header>
  <id_info>
    <org_study_id>HFEX 11.15</org_study_id>
    <nct_id>NCT01816022</nct_id>
  </id_info>
  <brief_title>Myeloproliferative Neoplasms and Bone Structure</brief_title>
  <official_title>Myeloproliferative Neoplasms and Bone Structure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical study to evaluate the effect of CMPN (Chronic myeloproliferative neoplasm)
      to the bone.

      The hypothesis is that patients with CMPN have a higher fracture-rate compared to the
      background population. We expect to find a lower BMD using conventional DXA scan (dual energy
      x-ray absorptiometry), and a change in other parameters using HR-pQCT (high-resolution
      peripheral quantitative computerized tomography).Biochemical bone markers is measured to
      support the hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical study to evaluate the effect of CMPN to the bone.

      Three individual cohorts are defined; a cohort consisting of 50 patients with Polycythemia
      Vera (PV), a cohort consisting of 50 patients with Essential Thrombocythemia (ET), and a
      cohort consisting of 25 patients with Primary Myelofibrosis (PMF).

      Patients are recruited from the Department of Hematology, Odense University Hospital.

      Interventions consist of:

        -  Conventional DXA scan to measure Bone Mineral Density (BMD).

        -  Experimental HR-pQCT to assess geometry, strength and microstructure of the bone in 3
           dimension.

        -  Blood-samples are collected and frozen for later analyses of Biochemical Bone Markers:
           1-CTP, Ctx, ALP (alkaline phosphatase)and P1NP.

      The outcome is compared to healthy control individuals.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD)</measure>
    <time_frame>1 day</time_frame>
    <description>Patients will undergo one DXA scan independent of time of CMPN diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Geometry, Strength and Micro-Structure of the bone.</measure>
    <time_frame>1 day</time_frame>
    <description>Patients will undergo one HR.pQCT indepedent of the time of the diagnosis of CMPN</description>
  </secondary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Polycythemia Vera</condition>
  <condition>Thrombocythemia, Essential</condition>
  <condition>Primary Myelofibrosis</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples to compare groups and to look for endocrine abnormalities
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Danish patients with CMPN
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PV (according to WHO 2008 criteria), only JAK2-pos.(Janus kinase 2)

          -  Diagnosis of ET (according to WHO 2008 criteria), only JAK2-pos.

          -  Diagnosis of PMF (according to WHO 2008 criteria)independent of JAK2-status.

        Exclusion Criteria:

          -  Pregnancy

          -  Bone Diseases (Mb. Pagets, Myelomatosis, MGUS (monoclonal gammopathy of undetermined
             significance), osteogenesis imperfecta, Prim. hyperparathyroidism, osteomalacia.

          -  Drugs (Prednisone&gt;3 mth, anti-osteoporotic drugs, anti-estrogen drugs.

          -  Presence of any psychologic condition or language barrier, which may interfere which a
             complete understanding, and arise ethnical considerations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Farmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Clinical Institute, University of Southern Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Farmer, MD</last_name>
    <phone>+45 22324276</phone>
    <email>mailtilsarah@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hanne Vestergaard, MD</last_name>
    <phone>+45 26258550</phone>
    <email>Hanne.Vestergaard@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Health Sciences, Institute of Clinical Research</name>
      <address>
        <city>Odense</city>
        <state>Region Syddanmark</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Farmer, MD</last_name>
      <phone>+45 22324276</phone>
      <email>mailtilsarah@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Hanne Vestergaard, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Sarah Farmer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>CMPN</keyword>
  <keyword>Fracture</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Biochemical Bone Markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

